Our management team has an extensive track record and experience in the research, development and delivery of RNA therapeutics, with over 50 years of combined experience in RNA delivery technologies and RNA therapeutics.

Robert W. Overell, Ph.D.

President and Chief Executive Officer

Read Bio

Mary G. Prieve, Ph.D.

Vice President of Biology and Interim Head of Research

Read Bio


Spencer Lemons

Head of Business Development

Read Bio

Robert W. Overell, Ph.D. has served as our president and member of our board of directors since 2006 and our chief executive officer since 2009. Prior to our first institutional financing in 2008, Dr. Overell was president of Foundation BioVentures LLC, which provided company formation and consulting services to startup companies, including us. Prior to that, Dr. Overell was a consultant, venture partner, then general partner, with Frazier Healthcare Ventures from 1996 to 2005, where he participated in raising over $600 million of venture capital and invested over $60 million in early-stage biotechnology companies. Dr. Overell has served on numerous corporate boards, including Array Biopharma Inc. (NASDAQ: ARRY) from 1998 to 2002, XenoPort, Inc. (NASDAQ: XNPT), which he co-founded in 1999, from 1999 to 2005, and Chimerix, Inc. (NASDAQ: CMRX) from 2004 to 2005.

Dr. Overell helped found Immunex Corporation’s gene therapy spinout, Targeted Genetics Corp., where he led product development and gene delivery programs from 1992 to 1996. Dr. Overell joined Immunex Corporation in 1984, where led programs in cell and molecular biology. He also led development of the first human immunodeficiency virus gene therapy trial in the world, which was approved by the Recombinant DNA Advisory Committee of the National Institutes of Health and the FDA in 1991. Dr. Overell obtained a B.Sc. in biological sciences from the University of Newcastle-upon-Tyne and a Ph.D. in biochemistry from the Institute of Cancer Research, University of London, United Kingdom.

Mary G. Prieve, Ph.D., joined PhaseRx in February 2008 as director of biology. Dr. Prieve leads the biology and formulation teams to develop polymer based nanoparticles for the delivery of siRNA and mRNA to target tissues of interest. Dr. Prieve has over a decade of experience in biochemical, cell-based, and molecular assay development as well as animal pharmacology. Therapeutic applications have focused in the areas of cancer and orphan liver disease at PhaseRx. From 2004 – 2007 she was a senior research scientist at Nastech Pharmaceutical Company Inc. In this role she led the in vivo pharmacology team which centered on peptide and lipid based delivery of siRNA for the treatment of inflammatory, infectious (influenza), and metabolic diseases.

From 2003 to 2004, Dr. Prieve was a visiting assistant professor at Smith College and a lecturer in cell and general biology courses at University of Washington and Seattle University. From 1999 – 2003 she did her post-doctoral training at the University of Washington in Dr. Randall Moon’s Laboratory in the area of Wnt signal transduction. She received a B.S. degree in chemistry from University of California, Santa Barbara and a Ph.D. in biological sciences from University of California, Irvine.

Spencer Lemons, founded Spira Consulting in Seattle in 2007 and has since helped create two dozen new high tech companies, including Agios Pharmaceuticals [NASDAQ:AGIO], Receptos [NASDAQ:RCPT] , Fate Therapeutics [NASDAQ:FATE] , Syros Pharmaceuticals [NASDAQ:SYRS] and Sapphire Energy. He has also negotiated $350MM in strategic relationships for biotechnology companies and non-profit institutions. Prior to founding Spira, Spencer was vice president of industry relations at the Fred Hutchinson Cancer Research Center working for Nobel Laureate, Leland Hartwell. Spencer previously directed similar efforts at Wake Forest University School of Medicine and NC State University. Spencer has served as vice president of the Association of University Technology Managers (AUTM) and on the AUTM Board.